Pathology: es-BC - TNBC - NA - all population;
es-BC - TNBC - NA - all population | |||
NeoTRIPaPDLA, 0 | IMpassion-031 (all population), 2020 | ||
atezolizumab plus carboplatin plus nab-paclitaxel | 1 | T1 | |
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide | 1 | T1 | |
carboplatin plus nab-paclitaxel | 0 | T0 | |
placebo plus SoC | 0 | T0 |